1. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 09

    The ABOUT™ Toolbox: toward the development of consumer-reported outcome measures that matter

    CHREA C.(1); SPIES E.(1); AFOLALU E.(1); BACSO A.(1); CLERC E.(1); MAINY N.(1); BINGGELI P.(1); WEITKUNAT R.(1); ACQUADRO C.(2); SALZBERGER T.(3); CANO S.(4); ABETZ-WEBB L.(5); ROSE J.(6)
    (1) PMI R&D, Philip Morris Products S.A., Neuchatel, Switzerland; (2) Mapi, an ICON plc Company, Lyon, France; (3) University of Economics and Business, Vienna, Austria; (4) ScaleReport, Ltd, Stotfold, U.K.; (5) Patient-Centered Outcomes Assessments, Ltd, Macclesfield Cheshire, U.K.; (6) Rose Research Center, Raleigh, U.S.A.
    Tobacco harm reduction promotes the substitution of reduced-risk products (RRPs) for cigarettes by adult smokers who would otherwise continue to smoke, while preventing RRP initiation among non-users. To operationalize this public health strategy, there ...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 11

    Development and validation of the ABOUT™–Dependence measurement instrument to assess perceived dependence on tobacco and nicotine products

    AFOLALU E.(1); CHREA C.(1); SALZBERGER T.(2); ABETZ-WEBB L.(3); CANO S.(4); WEITKUNAT R.(1); ROSE J.(5)
    (1) PMI R&D, Philip Morris Products S.A., Neuchatel, Switzerland; (2) University of Economics and Business, Vienna, Austria; (3) Patient-Centered Outcomes Assessments, Ltd, Macclesfield Cheshire, U.K.; (4) Modus Outcomes, Letchworth Garden City, U.K.; (5) Rose Research Center, Raleigh, U.S.A.
    The development of the ABOUT™–Dependence measurement instrument was initiated to enable assessment of perceived dependence associated with the use of different tobacco and nicotine products (TNPs) and in users of multiple TNPs. We initially developed a ...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 13

    Importance of e-liquid preparation and stability characterization for a combinatorial safety assessment approach of flavors in e-liquids

    GLABASNIA A.(1); DIANA P.(1); SMITH C.(2); MILLER J.H.(2); BIASIOLI M.(1); FRAUENDORFER F.(1); SCIUSCIO D.(1); MARTIN E.(1); POSPISIL P.(1); GUY P.(1); VANSCHEEUWIJCK P.(1); HOENG J.(1); KUMAR A.(2); LEE K.M.(2)
    (1) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (2) Altria Client Services LLC, Richmond, VA, U.S.A.
    Numerous flavorings are generally recognized as safe for use in food, but there is limited information available to evaluate their potential toxicity by inhalation. Consequently, gaining information on individual flavor safety levels is of significant ...
  4. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 45

    Meta-analysis of two biomarkers of exposure of tobacco products

    AYALA-FIERRO F.(1); ELAMIN A.(2); FROST-PINEDA K.(3); JIN T.(3); PRASAD G.L.(3); SARKAR M.(4); SCHMIDT E.(3); VERRON T.(5)
    (1) ITG Brands LLC, Greensboro, NC, U.S.A.; (2) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (3) RAI Services Company, Winston-Salem, NC, U.S.A.; (4) Altria Client Services LLC, Richmond, VA, U.S.A.; (5) SEITA - Imperial Brands, Paris, France
    In the context of tobacco products, broadly two types of biomarkers exist, biomarkers of exposure (BoE) and biomarkers of potential harm (BoPH). BoE measure exposure to tobacco constituents, e.g. carbon monoxide (CO) and nicotine equivalents (NEQs). The ...
  5. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 40 (also presented at TSRC 2019)

    A seven-month systems toxicology inhalation study in C57BL/6 mice demonstrates reduced pulmonary inflammation and emphysema following smoking cessation or switching to e-vapor aerosol exposures

    KUMAR A.(1); KOGEL U.(2); TALIKKA M.(2); SKOWRONEK A.(3); HOENG J.(2); PEITSCH M.C.(2); LEE K.M.(1)
    (1) Altria Client Services LLC, Richmond, VA, U.S.A.; (2) Philip Morris Products S.A., R&D, Neuchâtel, Switzerland; (3) Battelle, West Jefferson, OH, U.S.A.
    Cigarette smoking causes lung cancer, emphysema, and other serious diseases. While cessation remains the most effective approach to minimize smoking-related diseases, alternative nicotine delivery products that limit the generation of combustion by ...
  6. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 49

    The CORESTA in vitro test battery for combustible tobacco products: update from the 2004 Rationale and Strategy Report

    LEE K.M.(1); JORDAN K.G.(2); WIECZOREK R.(3); MOENNIKES O.(4); CLEMENTS J.(5); CROOKS I.(6); HASHIZUME T.(7); MILLER J.(8); WEBER E.(9); YOSHINO K.(7)
    (1) Altria Client Services, Richmond, VA, U.S.A.; (2) RAI Services Company, Winston-Salem, NC, U.S.A.; (3) Imperial Brands, Reemtsma Cigarettenfabriken GmbH, Hamburg, Germany; (4) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (5) Covance Laboratories Ltd, Harrogate, U.K.; (6) British American Tobacco (Investments) Ltd, R&D, Southampton, U.K.; (7) Japan Tobacco Inc., Yokohama, Kanagawa, Japan; (8) JT International SA, Geneva, Switzerland; (9) Ökolab, Vienna, Austria
    In 2004, the CORESTA In Vitro Toxicity Task Force issued a rationale and strategy report, commonly known as “the CORESTA in vitro test battery guideline”. The goals of this guideline were to: 1) develop the rationale and strategy for conducting in vitro ...
  7. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 57

    Cross-cultural equivalence of the ABOUT™–Perceived Risk instrument in seven languages

    CHREA C.(1); CANO S.(2); SALZBERGER T.(3); MAINY N.(1); ACQUADRO C.(4); POPIELNICKI A.(5); WEITKUNAT R.(1)
    (1) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (2) Modus Outcomes, Letchworth Garden City, U.K.; (3) University of Economics and Business, Vienna, Austria; (4) Mapi Research Trust, ICON plc, Lyon, France; (5) TransPerfect, Linguistic Validation Group, Boston, MA, U.S.A.
    The risk of smoking has long been well understood by consumers. However, it is important to measure the perceived risks by consumers of novel smoke-free alternatives to cigarettes. The ABOUT™–Perceived Risk instrument was developed to allow the ...
  8. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 58

    A consortium approach for consumer-reported outcome measures to assess tobacco- and nicotine-containing products

    ACQUADRO C.(1) on behalf of the CORESTA CROM Task Force: AYALA-FIERRO F.(2); BLACK R.(3); CAHOURS X.(4); CHREA C.(5); CURTIN G.(6); GILES L.(7); McCAFFREY S.(3); PARK C.H.(8); PRASAD K.(9); SHERWOOD N.(10); SHIFFMAN S.(11); SMITH J.(6); SPIES E.(5)
    (1) Mapi Research Trust, Lyon, France; (2) ITG Brands, Greensboro, NC, U.S.A.; (3) Altria Client Services, Richmond, VA, U.S.A.; (4) SEITA - Imperial Brands, Paris, France; (5) Philip Morris Products S.A., Neûchatel, Switzerland; (6) RAIS, Winston-Salem, NC, U.S.A.; (7) JT Int'l SA, Genève, Switzerland; (8) KT&G Research Institute, Daejeon, Republic of Korea; (9) British American Tobacco, Southampton, U.K.; (10) Neil Sherwood Consulting, Commugny, Switzerland; (11) Pinney Associates, Pittsburgh, PA, U.S.A.
    In the tobacco space, consumer-reported outcome measures (CROM) are essential for understanding motivations, subjective effects, and behavior. Such measures have become particularly important with the advent of candidate modified risk tobacco products ...
  9. TSRC, Tob. Sci. Res. Conf., 2019, 73, abstr. 022 (also presented at CORESTA SSPT2019)

    A seven-month systems toxicology inhalation study in C57BL/6 mice demonstrates reduced pulmonary inflammation and emphysema following smoking cessation or switching to e-vapor aerosol exposures

    KUMAR A.(1); KOGEL U.(2); TALIKKA M.(2); HOENG J.(2); PEITSCH M.(2); SKOWRONEK A.(3); LEE K.M.(1)
    (1) Altria Client Services, Richmond, VA, USA; (2) Philip Morris International, Neuchâtel, Switzerland; (3) Battelle, West Jefferson, OH, USA
    Cigarette smoking causes lung cancer, emphysema, and other serious diseases. While cessation remains the most effective approach to minimize smoking-related diseases, alternative nicotine delivery products that limit the generation of combustion by ...
  10. TSRC, Tob. Sci. Res. Conf., 2019, 73, abstr. 103

    Preclinical testing of flavors in e-vapor products - Part 1: Selection of representative flavor mixtures for toxicological evaluations using a structural grouping approach

    EHMAN K.D.(1); LANGSTON T.B.(1); KUMAR A.(1); LEE K.M.(1); SCIUSCIO D.(2); VANSCHEEUWIJCK P.(2); HOENG J.(2)
    (1) Altria Client Services, Richmond, VA, USA; (2) PMI R&D, Neuchâtel, Switzerland
    A variety of flavor ingredients are used in potentially reduced-risk tobacco or nicotine products, including e-vapor products. For this work, the ingredients were initially evaluated for quality and purity, which included assessment of food grade and GRAS ...